<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00722410</url>
  </required_header>
  <id_info>
    <org_study_id>CRKP-HMO-CTIL</org_study_id>
    <nct_id>NCT00722410</nct_id>
  </id_info>
  <brief_title>Probiotics for Eradication of Carbapenem Resistant Klebsiella Pneumonia</brief_title>
  <official_title>Safety and Efficacy Study of Eradication of Carbapenem Resistant Klebsiella Pneumonia From the Gastrointestinal Tract by Probiotics.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hadassah Medical Organization</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tel Aviv University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hadassah Medical Organization</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Infection by Klebsiella pneumonia producing class A carbapenemases is a major clinical and
      public health problem in Israel and worldwide. The aim of this study is to determine the
      safety and efficacy of alteration of the gut microflora by probiotics, alone or in
      combination with mechanical bowel cleansing, as a strategy to eradicate colonization of the
      gastrointestinal tract by CRKP. We hypothesize that administration of probiotics will
      decrease the rate of GI colonization by CRKP.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      CRKP colonization will be determined by culture and PCR of rectal swabs. The study will
      include 3 arms - no intervention, probiotics and mechanical bowel cleansing + probiotics.
      Followup examination of rectal swab samples for the presence of CRKP will be performed at 4
      weeks and 12 weeks from study entry.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>September 2008</start_date>
  <completion_date type="Anticipated">September 2010</completion_date>
  <primary_completion_date type="Anticipated">September 2010</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>A negative stool culture for Carbapenem resistant Klebsiella pneumonia.</measure>
    <time_frame>4 weeks.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>A negative stool culture and/or PCR assay for CRKP at twelve weeks after initiation of probiotics (i.e - 8 weeks after cessation of probiotic treatment).</measure>
    <time_frame>12 weeks beginning of intervention.</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Anti-Biotic Resistance</condition>
  <condition>Klebsiella Pneumoniae</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VSL#3 for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mechanical bowel cleansing followed by VSL#3 for 4 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>VSL#3</intervention_name>
    <description>A probiotic preparation.</description>
    <arm_group_label>B</arm_group_label>
    <arm_group_label>C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Polyethylene glycol</intervention_name>
    <description>Oral ingestion of 3 liters of polyethylene glycol solution.</description>
    <arm_group_label>C</arm_group_label>
    <other_name>New Meroken.</other_name>
    <other_name>Precolonoscopy solution.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects who are &gt; 18 years of age.

          2. Signing of informed consent by subject or legal custodian.

          3. Colonization of the gastrointestinal tract by CRKP as determined by stool culture or
             PCR of stool for the blakpc gene.

          4. Negative cultures for CRKP from extra-intestinal sites excluding urine.

        Exclusion Criteria:

          1. Subjects who have participated in another clinical trial within the last three months.

          2. Women with childbearing potential unless using adequate contraception (IUD, oral or
             depot contraceptive or barrier plus spermicide).

          3. Subjects who are pregnant or breast feeding.

          4. Subjects who will be unavailable for the duration of the trial, are likely to be
             non-compliant with the protocol, or who are felt to be unsuitable by the investigator
             for any other reason.

          5. Subjects with chronic diarrhea (&gt;4 weeks).

          6. Subjects with inflammatory bowel disease.

          7. Subjects whose stool is positive for Clostridium difficile toxin.

          8. Subjects receiving immunosuppressive treatment (i.e. corticosteroids; azathioprine or
             6-MP; cyclosporine; tacrolimus; OKT3, methotrexate; anti TNF agents; chemotherapy).

          9. Subjects who underwent solid organ or hematopoietic stem cell transplantation.

         10. Subjects with primary or secondary immunodeficiency disorders, including HIV.

         11. Subjects with chronic advanced cardiac, respiratory, renal or liver disease.

         12. Subjects with advanced malignant disease.

         13. Subjects with severe acute organ failure.

         14. Subjects in whom CRKP is isolated from sites other than stool or urine (i.e. blood,
             sputum or wound cultures).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maya Margalit, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hadassah Medical Organization</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maya Margalit, MD</last_name>
    <phone>972-50-7874561</phone>
    <email>mayam@hadassah.org.il</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hadas Lamberg, PhD</last_name>
    <phone>00 972 2 6777572</phone>
    <email>lhadas@hadassah.org.il</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hadassah Medical Organization</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Arik Tzukert, DMD</last_name>
      <phone>00 972 2 6776095</phone>
      <email>arik@hadassah.org.il</email>
    </contact>
    <contact_backup>
      <last_name>Hadas Lamberg, PhD</last_name>
      <phone>: 00 972 2 6777572</phone>
      <email>lhadas@hadassah.org.il</email>
    </contact_backup>
    <investigator>
      <last_name>Reut Zaguri, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <reference>
    <citation>Leavitt A, Navon-Venezia S, Chmelnitsky I, Schwaber MJ, Carmeli Y. Emergence of KPC-2 and KPC-3 in carbapenem-resistant Klebsiella pneumoniae strains in an Israeli hospital. Antimicrob Agents Chemother. 2007 Aug;51(8):3026-9. Epub 2007 Jun 11.</citation>
    <PMID>17562800</PMID>
  </reference>
  <reference>
    <citation>Manley KJ, Fraenkel MB, Mayall BC, Power DA. Probiotic treatment of vancomycin-resistant enterococci: a randomised controlled trial. Med J Aust. 2007 May 7;186(9):454-7.</citation>
    <PMID>17484706</PMID>
  </reference>
  <verification_date>July 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 23, 2008</study_first_submitted>
  <study_first_submitted_qc>July 24, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 25, 2008</study_first_posted>
  <last_update_submitted>July 24, 2008</last_update_submitted>
  <last_update_submitted_qc>July 24, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 25, 2008</last_update_posted>
  <responsible_party>
    <name_title>Maya Margalit</name_title>
    <organization>Hadassah Medical Organization</organization>
  </responsible_party>
  <keyword>Carbapenem</keyword>
  <keyword>resistant</keyword>
  <keyword>Klebsiella pneumoniae</keyword>
  <keyword>Carpapenemases</keyword>
  <keyword>Probiotics</keyword>
  <keyword>VSL3</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Klebsiella Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

